Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful ...

Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface). Each antibody produced by your immune system binds to a specific antigen and then ...

The main disadvantage of DNA vaccines is their poor immunogenicity. Several approaches including structural modification ... These innovative therapeutics include immune checkpoint blockers (ICBs), ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

“Despite the approval of chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies ... Secondary endpoints included overall response, duration of response, time to response, ...

Talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen ... pharmacodynamics, and immunogenicity. Progression-free survival ...

Researchers at the University of Colorado Anschutz Medical Campus have discovered that some CAR-T cells engineered to fight cancer and other conditions carry the memory of past encounters with ...

Universal Chimeric Antigen Receptor-Modified AT19 Cells is under clinical development by Chengdu USino Technology Biology and currently in Phase I for Unspecified B-Cell Lymphomas. According to ...

Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical ...

Tocilizumab also received FDA approval for the treatment of giant cell arteritis, polyarticular or systemic juvenile idiopathic arthritis, and cytokine release syndrome associated with chimeric ...